Sunday, 22 November 2026European Markets

GENFIT Stock Is 25% Up So Far Today

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Loading stream...

(vianews) - shares of genfit (cac 40: gnft.pa) rose by a staggering 25.55% to €4.82 at 11:54 est on friday, after two consecutive sessions in a row of gains. cac 40 is rising 0.69% to €7,363.31, after four sequential sessions in a row of gains. this seems, as yet, a somewhat bullish trend trading session today.

about genfit

genfit s.a., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. the company develops elafibranor, which is in phase iii clinical trial to treat patients with primary biliary cholangitis. it also engages in the development of nis4 technology for the diagnosis of nonalcoholic steatohepatitis (nash) and fibrosis; vs-01 for the treatment of urea cycle disorder (ucd) and organic acidemia disorder (oad); gns561, which is in phase 1b/2 trial to treat patients with cholangiocarcinoma (cca); and vs-01-aclf and nitazoxanide (ntz), which is in phase 1 trial to treat acute-on-chronic liver failure, as well as vs-02-he, which is in preclinical trial for the treatment of reduction of hyperammonemia and the stabilization of blood ammonia. the company has a licensing agreement with labcorp for the commercialization of nashnext, a blood-based molecular diagnostic test; and genoscience pharma to develop and commercialize the investigational treatment gns561 for cca. the company was incorporated in 1999 and is headquartered in loos, france.

earnings per share

as for profitability, genfit has a trailing twelve months eps of €-0.46.

more news about genfit (gnft.pa).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Published before we listed source documents with each article.
  2. Published 30 Jun 2023
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›